Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta‐Analysis
Obesity Reviews · 2025
DOI: 10.1111/obr.13946 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Obesity Reviews, 2025. Verfasst von Amir Hossein Faghfouri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Cardiometabolic Risk Factors, Overweight, Pediatric Obesity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 87 Literaturangaben.
Abstract (Originalsprache)
Background
Obesity has become a growing global health concern among young people. This meta‐analysis seeks to systematically assess the efficacy and safety of pharmaceutical interventions in improving body weight, body mass index (BMI), waist circumference (WC), diastolic blood pressure (DBP), fasting blood glucose (FBG), and lipid profiles, planned prior to data collection.
Methods
We conducted a comprehensive literature search on PubMed, Scopus, Embase, Web of Science, and the Cochrane Library, covering studies published up to September 2024. Randomized clinical trials (RCTs) were included if they reported efficacy of weight‐loss medications in youth populations aged 2–20 years. Direct and indirect evidence were synthesized using a frequentist framework.
Results
Pooled analysis on 30 RCTs showed that high dose phentermine/topiramate was more effective in reducing weight (MD: −15.8 kg; 95%CI: −19.17 to −12.43), BMI (MD = −5.35 kg/m2; 95% CI: −8.03, −2.67), WC (MD = −7.69 cm; 95% CI: −10.19, −5.18), and BMI percentile (MD: ‐20.25; 95%CI: −24.82 to 95% CI: −20.38 to −1.62) compared to placebo. Orlistat (MD = −1.81 mmHg; 95% CI: −2.94, −0.68), metformin (MD: −0.14 unit; 95%CI: −0.23 to −0.04), liraglutide (MD: −11.00 mg/dL; 95% CI: −20.38 to −1.62) were more effective in improving DBP, BMI‐z score, and FBG, respectively. Lipid profile and SBP were not affected by studied drugs.
Conclusion
High‐ and moderate‐dose phentermine/topiramate was more effective than a placebo in reducing anthropometric measures in youth living with overweight and obesity. Liraglutide and metformin result in a significant reduction in FBG levels compared to placebo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran.
- Student Research Committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
- Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
- Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
- School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Amir Hossein Faghfouri, Amin Mokari-Yamchi
Zitieren
APA
Faghfouri, A. H., Musazadeh, V., Mokari-Yamchi, A., Faramarzi, F., Pam, P., Shekari, S., Mahmoudzadeh, M., & Gheibi, S. (2025). Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta‐Analysis. Obesity Reviews. https://doi.org/10.1111/obr.13946
Vancouver
Faghfouri AH, Musazadeh V, Mokari-Yamchi A, Faramarzi F, Pam P, Shekari S, et al. Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta‐Analysis. Obesity Reviews. 2025. doi:10.1111/obr.13946
BibTeX
@article{Faghfouri2025,
author = {Faghfouri, Amir Hossein and Musazadeh, Vali and Mokari-Yamchi, Amin and Faramarzi, Fatemeh and Pam, Pedram and Shekari, Shima and Mahmoudzadeh, MohammadHadi and Gheibi, Shahsanam},
title = {Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta‐Analysis},
journal = {Obesity Reviews},
year = {2025},
doi = {10.1111/obr.13946}
}
EUVIMED